Browsing Pharmacy by Subject "Alzheimer's disease"
Now showing items 1-10 of 10
-
3-Phenylpyrazino[1,2-a]indol-1(2H)-ones as dual cholinesterase and amyloid aggregation inhibitors
(University of Waterloo, 2017-05-10)The year 2017, marks the 110th anniversary of the discovery of Alzheimer’s disease (AD)- a devastating neurodegenerative disease. Regardless of the significant advances made in the past century on the pathology of AD, the ... -
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitor use
(University of Waterloo, 2021-05-19)Background: Acquired long-QT syndrome (ALQTS) and its associated condition, torsades de pointes (TdP – a malignant cardiac arrhythmia), are associated with the use of certain medications. Case reports and pharmacodynamic ... -
Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease
(University of Waterloo, 2011-08-30)Alzheimer’s disease (AD) is a highly complex and rapidly progressive neurodegenerative disorder characterized by the systemic collapse of cognitive function and formation of dense amyloid-β (Aβ) plaques and neurofibrillary ... -
Design, Synthesis and Biological Evaluation of Novel Adamantane Derivatives as Potential Treatments for Alzheimer’s Disease
(University of Waterloo, 2017-02-14)Alzheimer’s disease (AD) is a complex, multifactorial, and rapidly neurodegenerative disorder characterized by cognitive impairment and progressive dementia. Its pathology was first characterized by Alois Alzheimer as “a ... -
Design, synthesis and biological evaluation of novel tricyclics as dual cholinesterase (ChE) and amyloid aggregation inhibitors with antioxidant properties
(University of Waterloo, 2014-12-12)Alzheimer’s disease (AD) is a complex neurodegenerative disease affecting the cholinergic region of the brain. Its prevalence is steadily increasing and it is becoming one of the highest costing diseases to modern society. ... -
Development of Novel Molecules as Modulators of Amyloid-β Aggregation
(University of Waterloo, 2021-09-08)Our brain is remarkably special and unique. It has billions of neurons that govern actions and reactions, and enables us to have thoughts, memories, and personality traits – outmost precious assets – that define who we are ... -
Endocannabinoids as Amyloid-Beta (Aβ) Aggregation Inhibitors
(University of Waterloo, 2022-05-13)The endocannabinoid system, including endogenous cannabinoids and their corresponding receptors, has received extensive attention in the last few years for their neuroprotective effect in the central nervous system. The ... -
The Interplay Between the Neuronal Plasma Membrane and Cell Signaling in Alzheimer’s Disease
(University of Waterloo, 2023-03-10)The lack of understanding in the molecular and cellular mechanisms of Alzheimer’s disease (AD) has hindered efforts towards finding treatments that effectively modify disease trajectory. Therapeutic development for AD has ... -
Lack of neuroprotective effects by platelet-derived growth factor against beta-amyloid induced toxicity uncovers a novel hypothesis of Alzheimer's disease pathology
(University of Waterloo, 2012-05-18)Aβ oligomer-induced neurotoxicity has become an important area of therapeutic development in treating Alzheimer’s disease. Platelet-derived growth factor (PDGF) has been shown to be able to protect neurons against several ... -
Metabolism, transport, and physiologically based pharmacokinetic modelling of novel tacrine derivatives
(University of Waterloo, 2015-08-26)Alzheimer’s disease (AD) is the most prevalent form of dementia affecting the elderly population, and its burden is rapidly growing both in Canada and worldwide. As a result, there is a substantial need for more effective ...